Open AccessThis article is
- freely available
Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
Department of Human Anatomy and Histology, University of Bari Medical School, Piazza G. Cesare, 11, Policlinico 70124, Bari, Italy
Received: 9 March 2010; in revised form: 21 April 2010 / Accepted: 22 April 2010 / Published: 22 April 2010
Abstract: Tyrosine kinase inhibitors are a new class of anticancer drugs, that are capable of directly interacting with the catalytic site of the target enzyme and thereby inhibiting catalysis. Therapeutically useful tyrosine kinase inhibitors are not specific for a single tyrosine kinase, but rather they are selective against a limited number of tyrosine kinases. The success of imatinib-mesylate (Gleevec®) for the treatment of patients with chronic myeloid leukemia has opened a intensive search for new small molecular compounds able to target other protein tyrosine kinases involved in the malignant transformation. This review article is focused on the use of tyrosine kinase inhibitors as antiangiogenic molecules in the treatment of multiple myeloma.
Keywords: angiogenesis; antiangiogenesis; multiple myeloma; tyrosine kinase inhibitors
Citations to this Article
Cite This Article
MDPI and ACS Style
Ribatti, D. Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma. Pharmaceuticals 2010, 3, 1225-1231.
Ribatti D. Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma. Pharmaceuticals. 2010; 3(4):1225-1231.
Ribatti, Domenico. 2010. "Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma." Pharmaceuticals 3, no. 4: 1225-1231.